Genmab-partner Seagen strikes deal on Chinese rights for Tivdak
Exclusive commercial rights in China for the cervical cancer treatment jointly developed by Seagen and Genmab have been obtained by Zai Lab.
by marketwire, translated by daniel pedersen
US-based Seagen has entered a regional strategic collaboration and licensing deal concerning cervical cancer treatment Tivdak with Zai Lab, a pharmaceutical company based in China, a company press release announces.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.